TIDMHIK
RNS Number : 9001F
Hikma Pharmaceuticals Plc
21 June 2012
Annex DTR3
Notification of Transactions of Directors/Persons Discharging
Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital
letters.
1.
Name of the issuer
HIKMA PHARMACEUTICALS PLC
2.
State whether the notification relates to (i) a
transaction notified in accordance with DTR 3.1.2 R,
(ii) a disclosure made in accordance
LR 9.8.6R(1) or
(iii) a disclosure made in accordance with section 793 of the
Companies Act (2006).
(i) & (iii)
3.
Name of person discharging managerial
responsibilities/director
SAMIH DARWAZAH
4.
State whether notification relates to a person
connected with a person discharging managerial
responsibilities/director named in 3 and identify the connected
person
N/A
5.
Indicate whether the notification is in respect of a holding of
the person referred to in 3 or 4 above or in respect of a
nonbeneficial
interest 1
3 ABOVE
6.
Description of shares (including class), debentures or
derivatives or financial instruments relating to shares
ORDINARY SHARES OF 10P EACH
7.
Name of registered shareholders(s) and, if more than one, the
number of shares held by each of them
CREDIT SUISSE (BNP PARIBAS)
8.
State the nature of the transaction
MARKET DISPOSAL OF 195,447 ORDINARY SHARES
9.
Number of shares, debentures or financial
instruments relating to shares acquired
N/A
10.
Percentage of issued class acquired (treasury shares of that
class should not be taken into account when calculating
percentage)
N/A
11.
Number of shares, debentures or financial
instruments relating to shares disposed
195,447
12.
Percentage of issued class disposed (treasury shares of that
class should not be taken into account when calculating
percentage)
0. 099%
13.
Price per share or value of transaction
GBP6.49
14.
Date and place of transaction
15 JUNE 2012, LONDON
15.
Total holding following notification and total percentage
holding following notification (any treasury shares should not be
taken into account when calculating percentage)
2,136,299
1.08%
16.
Date issuer informed of transaction
19 JUNE 2012
If a person discharging managerial responsibilities has been
granted options by the issuer
complete the following boxes
17.
Date of grant
N/A
18.
Period during which or date on which exercisable
N/A
19.
Total amount paid (if any) for grant of the option
N/A
20.
Description of shares or debentures involved (class and
number)
N/A
21.
Exercise price (if fixed at time of grant) or
indication that price is to be fixed at the time of exercise
N/A
22.
Total number of shares or debentures over which options held
following notification
N/A
23.
Any additional information
N/A
24.
Name of contact and telephone number for queries
Peter Speirs 0207 399 2772
Name of authorised official of issuer responsible for making
notification
Peter Speirs
Date of notification 21 June 2012
Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.
(1)
An issuer making a notification in respect of a transaction
relating to the shares or debentures of the issuer should complete
boxes 1 to 16, 23 and 24.
(2)
An issuer making a notification in respect of a derivative
relating the shares of the issuer should complete boxes 1 to 4, 6,
8, 13, 14, 16, 23 and 24.
(3)
An issuer making a notification in respect of options granted to
a director/person discharging managerial responsibilities should
complete boxes 1 to 3 and 17 to 24.
(4)
An issuer making a notification in respect of a financial
instrument relating to the shares of the issuer (other than a
debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16,
23 and 24.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBSGDLDGDBGDB
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024